Skip to Main Content

Author Details

Zafeiris Zafeiriou
Theageneion Anticancer Hospital
2013
39
25
PMIDPaper TitleJournal TitlePublished Year
37760481Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study.Cancers (Basel)2023
34940079Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study).Curr Oncol2021
31605223Genetic Analysis of Circulating Tumour Cells.Recent Results Cancer Res2020
31874108Genomics of lethal prostate cancer at diagnosis and castration resistance.J Clin Invest2020
31609136First trimester neutrophil to lymphocyte ratio (NLR) and pregnancy outcome.J Obstet Gynaecol2020
30614314First trimester neutrophil-to-lymphocyte ratio (NLR) and pregnancy outcomes in medically assisted reproduction (MAR): a case control study.Gynecol Endocrinol2019
31152158Publisher Correction: The long tail of oncogenic drivers in prostate cancer.Nat Genet2019
30340782Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.Eur Urol2019
29610475The long tail of oncogenic drivers in prostate cancer.Nat Genet2018
29911685Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers.Eur Urol Oncol2018
30179225Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.J Clin Invest2018
30068710SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.Clin Cancer Res2018
30093450Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.Clin Cancer Res2018
30382943Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.J Clin Invest2018
27539393Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.BJU Int2017
28383660CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.Ann Oncol2017
28450425Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.Cancer Discov2017
28571827Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital.Clin Genitourin Cancer2017
27875103Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.Radiology2017
26873496Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents.Drugs2016
27117751Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.Eur Urol2016
27246360Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.Clin Genitourin Cancer2016
26965561Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.Eur Urol2016
25563847Switching and withdrawing hormonal agents for castration-resistant prostate cancer.Nat Rev Urol2015
28843286Integrative Clinical Genomics of Advanced Prostate Cancer.Cell2015
26567358CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer.Clin Cancer Res2015
26510020DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.N Engl J Med2015
26537258Plasma AR and abiraterone-resistant prostate cancer.Sci Transl Med2015
26181263Cabozantinib-Getting Under the Skin of Cutaneous Toxicity.JAMA Oncol2015
26000489Integrative clinical genomics of advanced prostate cancer.Cell2015
25719830Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.Br J Cancer2015
25454616PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.Eur Urol2015
25538172Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.Ann Oncol2015
24685433External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone.Eur Urol2014
25314055Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.Br J Cancer2014
25182808Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer.BMC Cancer2014
24531559Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG).Cancer Chemother Pharmacol2014
22936063Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer.Mod Pathol2013
23604531A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.Cancer Chemother Pharmacol2013
  • 1 - 39 of 39

Recommended Authors

Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Career Start Year 2013
Number of shared co-authors 8
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 10
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 14
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 9
Channing J Paller
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 15
Ashley E Ross
Northwestern University
Career Start Year 2003
Number of shared co-authors 24
Rahul Aggarwal
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 32
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 7
Kim N Chi
University of British Columbia
Career Start Year 2000
Number of shared co-authors 37
Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2000
Number of shared co-authors 44
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 26
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2000
Number of shared co-authors 42
Joshua M Lang
19University of Wisconsin Carbone Cancer Center.
Career Start Year 2000
Number of shared co-authors 22
David T Miyamoto
Massachusetts General Hospital
Career Start Year 2000
Number of shared co-authors 4
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 8
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 37
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Career Start Year 1997
Number of shared co-authors 17
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 22
Michael A Carducci
Johns Hopkins School of Medicine
Career Start Year 1995
Number of shared co-authors 25
Inge M van Oort
Radboud University Medical Center
Career Start Year 1995
Number of shared co-authors 18
Andries M Bergman
The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital
Career Start Year 1994
Number of shared co-authors 17
Edwin M Posadas
Cedars-Sinai Medical Center
Career Start Year 1993
Number of shared co-authors 19
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 17
Urban Emmenegger
Odette Cancer Centre
Career Start Year 1991
Number of shared co-authors 7
Fred Saad
University of Montreal Health Center
Career Start Year 1990
Number of shared co-authors 28
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 29
Celestia S Higano
University of Washington and Fred Hutchinson Cancer Research Center
Career Start Year 1987
Number of shared co-authors 35
Eric J Small
University of California san francisco
Career Start Year 1985
Number of shared co-authors 42
Mario A Eisenberger
Johns Hopkins University
Career Start Year 1977
Number of shared co-authors 29
Ronald de Wit
Erasmus MC Cancer Institute
Career Start Year 1972
Number of shared co-authors 17

Collaborators

Johann S de Bono
The Institute for Cancer Research
Co-authored papers 31
Joaquin Mateo
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Co-authored papers 20
Susana Miranda
The Institute of Cancer Research
Co-authored papers 16
Nina Tunariu
The Institute of Cancer Research
Co-authored papers 16
Roberta Ferraldeschi
Astex Pharmaceuticals
Co-authored papers 14
Raquel Perez-Lopez
Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus
Co-authored papers 13
Gerhardt Attard
The Institute of Cancer Research
Co-authored papers 11
Suzanne Carreira
The Institute of Cancer Research
Co-authored papers 10
Penny Flohr
The Institute of Cancer Research
Co-authored papers 10
Adam Sharp
The Institute for Cancer Research
Co-authored papers 9
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 9
Wei Yuan
The Institute for Cancer Research
Co-authored papers 9
Dan R Robinson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 8
Mark A Rubin
University of Bern
Co-authored papers 8
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers 7
Gunther Boysen
Co-authored papers 7
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 6
Howard I Scher
Memorial Sloan Kettering Cancer Center
Co-authored papers 6
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 6
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 6
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Co-authored papers 6
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 6
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 6
Wassim Abida
Memorial Sloan Kettering Cancer Center
Co-authored papers 6
Matthew Clarke
Co-authored papers 5
Francesca Demichelis
University of Trento
Co-authored papers 5
Yi-Mi Wu
University of Michigan Medical School ann arbor
Co-authored papers 5
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 4
Jianjiong Gao
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Co-authored papers 4
Release 1.2